
Last updated: 2026-10-01 02:43:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Latigo Biotherapeutics, Inc. (LTGO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $16,70, with a market capitalization of $1,16B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $16,19 to $25,93. This page covers its latest market performance, valuation, price trends and company information.
$1,16B | |
$18,04 | |
$25,93 | |
$16,19 | |
$18,10 | |
497,22K | |
387,50K | |
-- | |
$25,93 | |
$16,19 | |
-- | |
-- |
Latigo Biotherapeutics, Inc. (LTGO) last closed at $18,10 as of 2026-09-30 23:56:00, unchanged from the previous close of $18,10.
During the latest regular trading session, LTGO traded between $16,19 and $25,93, with a volume of 497,22K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Latigo Biotherapeutics, Inc. (LTGO) moved from $21,11 to $16,70, representing a decline of 20,91% ($4,41).
The stock traded between $16,19 and $23,11 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 411,28 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 5,2%
LTGO is currently trading at $16,70, placing it 5,2% of the way from its 52-week low of $16,19 to its 52-week high of $25,93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Latigo Biotherapeutics, Inc. (LTGO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.